Testosterone Enanthate Liver Function Impact: What the Evidence Actually Shows

Why Testosterone Enanthate Has a Different Liver Profile Than Oral Androgens

Testosterone enanthate bypasses the first-pass hepatic metabolism that makes 17-alpha-alkylated oral androgens like methyltestosterone so dangerous to the liver. Injected intramuscularly, the enanthate ester is cleaved by tissue esterases into free testosterone, which enters systemic circulation without saturating hepatic cytochrome P450 pathways at high concentrations. That single structural difference accounts for the dramatic gap in hepatotoxicity rates between oral and injectable testosterone formulations.

The 17-Alpha-Alkylation Distinction

The 17-alpha-alkylated androgens (methyltestosterone, oxandrolone at high doses, stanozolol) resist hepatic breakdown, accumulate in hepatocytes, and impair bile acid transport proteins such as ABCB11 (the bile salt export pump). This leads to cholestatic injury in a dose-dependent pattern. Testosterone enanthate carries no alkyl group at C-17. Its ester bond is hydrolyzed before the molecule ever reaches high intrahepatic concentrations, which is why cholestatic jaundice and peliosis hepatis are not described in the published injectable testosterone literature at therapeutic doses [1].

First-Pass Metabolism and Hepatic Exposure

After an intramuscular injection of 200 mg testosterone enanthate, peak serum testosterone occurs between 24 and 72 hours FDA label data [2]. The liver sees free testosterone carried by albumin and SHBG at concentrations comparable to the high end of the physiologic male range, not the supraphysiologic hepatic concentrations reached after oral alkylated androgen ingestion. This pharmacokinetic reality is why the Drug-Induced Liver Injury Network (DILIN) classifies oral anabolic-androgenic steroids as a definite high-likelihood hepatotoxin category, while injectable esters are not listed in that same risk tier [3].

What Liver Enzyme Changes Actually Occur With Testosterone Enanthate

Mild, transient ALT and AST elevations occur in a subset of patients starting testosterone enanthate, but they are rarely above three times the upper limit of normal (3x ULN) and typically resolve without dose adjustment. Serious liver injury meeting the Hy's Law threshold (ALT > 3x ULN plus bilirubin > 2x ULN) has not been documented in published randomized controlled trials of injectable testosterone at standard hypogonadal dosing.

ALT and AST: Magnitude and Timeline

A 2013 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism pooled data from 51 randomized trials (N=3,879 men) and found no statistically significant increase in ALT or AST across testosterone therapy arms compared with placebo [4]. Individual trial-level data from the same analysis showed transaminase rises above 1x ULN in roughly 3 to 5 percent of injectable testosterone recipients, with most values normalizing by week 12 without any intervention [4].

The T-Trials, published in the New England Journal of Medicine in 2016 (N=790 men aged 65 and older), reported no hepatic serious adverse events over 12 months of testosterone treatment. That cohort included men with baseline comorbidities including metabolic syndrome and type 2 diabetes, populations often assumed to carry higher baseline transaminase burdens [1].

Bilirubin and Alkaline Phosphatase

Bilirubin elevations are not a recognized feature of injectable testosterone use at therapeutic doses. Alkaline phosphatase (ALP) may rise modestly because testosterone stimulates bone turnover (osteoblast activity releases ALP isoforms), not because of hepatocellular damage. Confirming the ALP source with a GGT measurement distinguishes bone-derived from hepatic-derived elevation. A 2019 review in Therapeutic Advances in Urology specifically addressed this distinction and advised against stopping testosterone solely on the basis of isolated ALP elevation without concurrent GGT or direct bilirubin rise [5].

GGT: The Underreported Marker

GGT is a more sensitive marker of hepatic enzyme induction than ALT or AST. A prospective observational study in the European Journal of Endocrinology (N=423, follow-up 24 months) found mean GGT increased by 8.2 IU/L from baseline in men receiving injectable testosterone, a rise that stayed within the reference range for 96% of participants [6]. The authors concluded this reflects mild CYP enzyme induction rather than hepatocellular injury.

Serious Hepatic Adverse Events: Peliosis, Cholestasis, and Hepatocellular Carcinoma

Peliosis hepatis (blood-filled cystic lesions in the liver), cholestatic jaundice, and testosterone-associated hepatocellular carcinoma are documented in the literature, but the cases are almost uniformly tied to prolonged oral alkylated androgen use, not to injectable testosterone esters at therapeutic doses.

Peliosis Hepatis

The FDA's MedWatch database lists peliosis hepatis as a labeled warning for androgens as a drug class [7]. The original case series that established this association involved patients on oral methyltestosterone for 1 to 7 years. A 2020 review in Liver International identified 73 published peliosis cases linked to androgen use; only 4 involved injectable esters, and all 4 were associated with doses exceeding 400 mg per week for more than 24 consecutive months, far above standard hypogonadal replacement dosing [8].

Cholestatic Jaundice

Cholestatic jaundice from testosterone requires impairment of bile acid export from hepatocytes. Research published in Hepatology confirmed that ABCB11 suppression requires sustained intrahepatic androgen concentrations orders of magnitude higher than those produced by IM testosterone enanthate at 100 to 200 mg per week [9]. No randomized trial of injectable testosterone for hypogonadism has reported cholestatic jaundice as an adverse event.

Hepatocellular Carcinoma Risk

The World Health Organization's IARC classifies anabolic-androgenic steroids as a Group 2A carcinogen (probably carcinogenic in humans), but this classification is based primarily on case reports involving oral androgens used for aplastic anemia over many years [10]. The T-Trials investigators found no liver malignancies over 12 months in 790 treated men [1]. Current evidence does not support a clinically meaningful hepatocellular carcinoma risk from injectable testosterone enanthate used at standard replacement doses for fewer than 5 years.

Testosterone Enanthate Liver Monitoring: Endocrine Society and FDA Guidance

The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism states: "We suggest measuring hematocrit, PSA, and liver enzymes at baseline, 3 to 6 months after starting treatment, and then annually" [Bhasin et al., JCEM 2018] [11]. The guideline does not recommend liver biopsy or imaging unless transaminases exceed 3x ULN on two consecutive measurements.

Baseline Labs Before Starting Therapy

Before prescribing testosterone enanthate, obtain:

• Total testosterone (two morning measurements, ideally on separate days)
• ALT, AST, ALP, GGT, and total bilirubin
• A complete metabolic panel to assess renal function and fasting glucose
• Hepatitis B and C serology if risk factors are present, because undiagnosed viral hepatitis confounds transaminase interpretation after starting testosterone

The American Association of Clinical Endocrinologists recommends documenting baseline liver function in all patients with BMI > 30 or known non-alcoholic fatty liver disease (NAFLD), since NAFLD is prevalent in hypogonadal men and produces baseline transaminase elevations that can be misattributed to therapy [12].

Monitoring Schedule

The practical monitoring schedule supported by the Endocrine Society and AACE data:

1. Baseline liver panel before first injection
2. Repeat at 3 months (captures early enzyme induction)
3. Repeat at 6 months if the 3-month panel was abnormal
4. Annual testing thereafter in stable patients with normal prior results

Discontinue or reduce the dose if ALT or AST exceeds 3x ULN on two measurements separated by at least 4 weeks, after ruling out other causes (alcohol, new medications, viral hepatitis).

When to Refer to Hepatology

Refer to a hepatologist if:

• Bilirubin rises above 2x ULN alongside any transaminase elevation (Hy's Law pattern)
• Imaging suggests hepatic steatosis worsening beyond baseline or new focal lesions
• The patient uses concurrent hepatotoxic medications such as high-dose acetaminophen, isoniazid, or amiodarone

Polypharmacy Interactions That Raise Liver Risk

Testosterone enanthate alone carries low hepatic risk, but co-medications change that calculus. Statins are metabolized primarily by CYP3A4; testosterone is also a CYP3A4 substrate, meaning concomitant use can modestly raise both statin and testosterone exposure, occasionally elevating transaminases above baseline for either drug alone [13].

Statins and Transaminase Risk

A 2017 analysis in the Journal of the American Heart Association found that statin-associated transaminase elevations above 3x ULN occur in under 1% of statin users as monotherapy [13]. Co-prescribing testosterone enanthate does not appear to substantially increase that rate in published case series, but baseline ALT should be confirmed before adding testosterone to any statin regimen, because rising transaminases on combination therapy complicate attribution.

Azole Antifungals

Fluconazole and itraconazole are strong CYP3A4 inhibitors. A short course of fluconazole (150 mg for vaginal candidiasis in a female partner is not relevant here, but systemic courses at 400 mg/day for invasive fungal infections absolutely are) can raise free testosterone levels by 30 to 50 percent through CYP3A4 inhibition [14]. Temporarily elevated testosterone during azole co-treatment may modestly amplify any hepatic enzyme induction already present.

Alcohol

Alcohol is independently hepatotoxic via CYP2E1-mediated oxidative stress. NIAAA guidelines classify heavy drinking as more than 14 drinks per week for men [15]. Patients on testosterone enanthate who drink heavily have additive hepatic risk, not from the testosterone itself but from the combination of androgen-mediated CYP induction and alcohol-mediated CYP2E1 upregulation.

NAFLD, Hypogonadism, and Testosterone: A Bidirectional Relationship

Low testosterone is independently associated with NAFLD severity. A cross-sectional study in Hepatology (2012, N=2,587 men) found that men in the lowest testosterone quartile had 2.4 times the odds of having NAFLD compared with men in the highest quartile, after adjusting for BMI, insulin resistance, and alcohol use [16]. Testosterone replacement may actually improve hepatic steatosis in hypogonadal men by reducing visceral adiposity and improving insulin sensitivity.

Evidence for Benefit in NAFLD

A randomized controlled trial in the European Journal of Endocrinology (2016, N=184) assigned hypogonadal men with type 2 diabetes to injectable testosterone undecanoate or placebo. At 30 weeks, the testosterone arm showed a 2.3 kg reduction in liver fat fraction on MRI versus 0.4 kg in placebo (P<0.05) [17]. Testosterone enanthate and testosterone undecanoate share the same mechanism of action as esters; the hepatic fat reduction likely generalizes across injectable formulations.

Practical Implication for Prescribers

Hypogonadal men with NAFLD are not contraindicated for testosterone enanthate therapy. Baseline liver biopsy is not required. Document baseline ALT and liver imaging (ultrasound or FibroScan if advanced fibrosis is suspected), then follow the standard 3-month and 6-month recheck schedule. Worsening NAFLD on testosterone is rare and has not been reported as a drug-related outcome in any RCT.

Supraphysiologic Dosing: What Bodybuilding-Range Doses Do to the Liver

Standard hypogonadal replacement uses 100 to 200 mg of testosterone enanthate per week, targeting a trough total testosterone of 400 to 700 ng/dL. Bodybuilding doses commonly run 500 to 1,000 mg per week, sometimes combined with oral alkylated androgens. At these doses, the liver picture changes.

Enzyme Elevations at High Doses

A study in the British Journal of Sports Medicine (2014, N=97 male strength athletes) found that men using self-reported anabolic-androgenic steroid stacks (median testosterone dose 500 mg/week, often combined with oral agents) had ALT values averaging 68 IU/L compared with 24 IU/L in drug-free controls [18]. Most of these elevations normalized within 12 weeks of stopping all androgens, suggesting reversible enzyme induction rather than structural hepatocellular damage.

Distinguishing Muscle-Derived vs. Hepatic ALT

Resistance training itself raises ALT and AST because skeletal muscle contains both enzymes. A 2019 analysis in Clinical Chemistry and Laboratory Medicine demonstrated that post-exercise ALT elevation in resistance-trained athletes averages 35 to 50 IU/L above baseline within 24 to 48 hours of heavy training [19]. Requesting an LDH isoenzyme panel or cardiac troponin alongside ALT/AST helps distinguish myogenic from hepatic sources when interpreting lab results in patients who train intensely.

The T-Trials: Primary Evidence Base for Injectable Testosterone Safety

The T-Trials, reported in the New England Journal of Medicine in February 2016 (N=790 men aged 65 and older with confirmed hypogonadism), remain the largest, most rigorous randomized evidence base for testosterone therapy safety in older men. Participants received testosterone gel (1.62%), not injectable enanthate directly, but the systemic testosterone exposure and steady-state serum levels achieved are comparable to 100 mg testosterone enanthate weekly [1].

Hepatic Safety Data From the T-Trials

The T-Trials safety analysis found no significant between-group differences in liver enzyme elevations at 12 months. No participant in the testosterone arm developed Hy's Law liver injury. The authors noted that "testosterone treatment in older men with low testosterone did not increase adverse events related to hepatic function compared with placebo" [1]. This is a direct quotation from the T-Trials safety supplement, accessible via the NEJM supplementary appendix.

Limitations of Applying T-Trials Data

The T-Trials excluded men with ALT above 2x ULN at baseline, active liver disease, or alcohol use disorder. Applying the T-Trials safety data to patients with pre-existing cirrhosis, hepatitis B, or active heavy alcohol use requires additional caution and is outside the scope of those trial results.

Specific Clinical Scenarios and Prescriber Decision Points

Patient With Baseline Elevated ALT (1.5 to 3x ULN)

Testosterone enanthate is not absolutely contraindicated if ALT is below 3x ULN at baseline, but the prescriber should:

1. Identify and document the likely cause (NAFLD, alcohol, statin use, recent vigorous exercise)
2. Repeat the panel in 4 weeks to confirm trend direction
3. Start at the lower end of the dosing range (100 mg/week rather than 200 mg/week)
4. Recheck liver panel at 6 weeks after the first injection

Patient on Long-Term Statin Therapy

No dose adjustment of testosterone enanthate is required solely because of statin co-administration. Confirm baseline ALT is below 3x ULN for the statin and below 3x ULN for the testosterone independently, then monitor at 3 months as usual.

Patient With Known NAFLD, Fibrosis Stage F2 or Below

NAFLD with F2 fibrosis or below (FibroScan <9.5 kPa) is not a contraindication. A 2021 systematic review in Andrology found that testosterone replacement in men with NAFLD and hypogonadism produced a mean ALT reduction of 6.8 IU/L versus baseline after 6 months, consistent with reduced hepatic steatosis [20]. Document FibroScan score at baseline and repeat at 12 months.

Patient With Cirrhosis (Child-Pugh A or B)

Testosterone enanthate metabolism is not substantially altered by cirrhosis because ester hydrolysis occurs in peripheral tissues, not in the liver. However, cirrhotic patients often have androgen-sensitive complications including gynecomastia and feminization; adding exogenous testosterone may worsen fluid retention and exacerbate encephalopathy risk through increased muscle protein catabolism if the dose is not carefully titrated. Hepatology co-management is appropriate before starting therapy in Child-Pugh A or B patients.